Nuvalent, Inc. (NASDAQ:NUVL – Get Rating) insider Darlene Noci sold 1,604 shares of the stock in a transaction on Wednesday, August 24th. The stock was sold at an average price of $17.03, for a total value of $27,316.12. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Darlene Noci also recently made the following trade(s):
Get
Nuvalent alerts:
- On Friday, July 15th, Darlene Noci sold 3,782 shares of Nuvalent stock. The stock was sold at an average price of $17.29, for a total value of $65,390.78.
- On Monday, July 18th, Darlene Noci sold 100 shares of Nuvalent stock. The stock was sold at an average price of $17.07, for a total value of $1,707.00.
- On Thursday, July 7th, Darlene Noci sold 16,800 shares of Nuvalent stock. The stock was sold at an average price of $17.61, for a total value of $295,848.00.
Nuvalent Trading Down 3.4 %
Shares of Nuvalent stock opened at $16.88 on Friday. The business's fifty day simple moving average is $15.47 and its 200 day simple moving average is $13.34. Nuvalent, Inc. has a 12 month low of $7.09 and a 12 month high of $40.82.
Nuvalent (NASDAQ:NUVL – Get Rating) last posted its earnings results on Wednesday, August 10th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.05. On average, sell-side analysts predict that Nuvalent, Inc. will post -1.73 earnings per share for the current year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its stake in Nuvalent by 115.6% during the 1st quarter. Vanguard Group Inc. now owns 1,637,507 shares of the company's stock valued at $22,745,000 after purchasing an additional 877,835 shares during the last quarter. Fairmount Funds Management LLC grew its position in Nuvalent by 46.3% in the first quarter. Fairmount Funds Management LLC now owns 1,338,393 shares of the company's stock worth $18,590,000 after acquiring an additional 423,779 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Nuvalent by 9,445.3% in the fourth quarter. JPMorgan Chase & Co. now owns 391,645 shares of the company's stock worth $7,457,000 after purchasing an additional 387,542 shares during the last quarter. BlackRock Inc. lifted its stake in Nuvalent by 30.2% in the first quarter. BlackRock Inc. now owns 1,257,463 shares of the company's stock worth $17,466,000 after purchasing an additional 291,821 shares during the last quarter. Finally, Millennium Management LLC bought a new stake in shares of Nuvalent during the second quarter valued at approximately $3,523,000.
Wall Street Analyst Weigh In
Separately, BMO Capital Markets assumed coverage on Nuvalent in a research report on Thursday, June 23rd. They issued an "outperform" rating and a $28.00 target price for the company.
Nuvalent Company Profile
(Get Rating)
Nuvalent, Inc, a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial.
Featured Stories
- Get a free copy of the StockNews.com research report on Nuvalent (NUVL)
- 3 Reasons Dollar General's Rally Has Legs
- Salesforce Stock Could Have Long Term Potential After Earnings
- Should AbbVie Inc. Have a Place in Your Dividend Portfolio?
- Is PayPal A Buy After Post-Earnings Price Jump?
- Williams-Sonoma's High-End Consumers Are Still Spending
Receive News & Ratings for Nuvalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvalent and related companies with MarketBeat.com's FREE daily email newsletter.
